Definium Therapeutics, Inc.
DFTX
Rank in Stocks
#3601
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Share Price
$35.18
Market Cap
$4.73B
Change (1 day)
6.69%
Change (1 year)
221.68%
Country
US
Trade Definium Therapeutics, Inc. (DFTX)
Category
Healthcare
P/B ratio for Definium Therapeutics, Inc. (DFTX)
P/B ratio as of 2026 TTM: 0
According to Definium Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Definium Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
